PRESS RELEASE published on 08/17/2023 at 22:15, 2 years 7 months ago Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
PRESS RELEASE published on 08/03/2023 at 12:30, 2 years 7 months ago Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
PRESS RELEASE published on 07/13/2023 at 13:00, 2 years 8 months ago Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
PRESS RELEASE published on 07/05/2023 at 13:00, 2 years 8 months ago Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345
PRESS RELEASE published on 07/03/2023 at 07:00, 2 years 8 months ago Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine
PRESS RELEASE published on 06/22/2023 at 22:05, 2 years 9 months ago Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine
PRESS RELEASE published on 06/05/2023 at 14:00, 2 years 9 months ago Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
PRESS RELEASE published on 06/01/2023 at 22:05, 2 years 9 months ago Moderna to Present at Upcoming Conferences in June 2023
PRESS RELEASE published on 05/30/2023 at 14:00, 2 years 9 months ago Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
PRESS RELEASE published on 05/19/2023 at 13:00, 2 years 10 months ago Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
Published on 03/27/2026 at 12:30, 19 minutes ago Pasinex Closes First Tranche of Over-Subscribed Non-Brokered Private Placement
Published on 03/27/2026 at 12:00, 49 minutes ago Temas Appoints Scientific Advisory Board to Accelerate RCL Commercialisation and Global Development
Published on 03/27/2026 at 11:00, 1 hour 49 minutes ago RE Royalties Announces Strategic Review to Evaluate Path for Long-Term Value Creation
Published on 03/27/2026 at 09:30, 3 hours 19 minutes ago Amap Street Stars Launches Macao Authentic Delicacies Ranking to Drive Cultural-Tourism Innovation in the Greater Bay Area
Published on 03/27/2026 at 11:45, 1 hour 4 minutes ago Second National Showcase of Outstanding Works from China’s Rare Operatic Genres Held
Published on 03/27/2026 at 11:45, 1 hour 4 minutes ago Deuxième édition du Festival des chefs-d’œuvre des genres rares de l’opéra chinois Un événement dédié aux opéras traditionnels en voie de disparition
Published on 03/27/2026 at 11:40, 1 hour 8 minutes ago Disposal of shares in Pension Insurance Corporation Group Limited
Published on 03/27/2026 at 11:19, 1 hour 29 minutes ago The Payments Group Holding advances strategic initiatives successfully
Published on 03/27/2026 at 07:00, 5 hours 49 minutes ago WEB SA - CONVOCATION ASSEMBLEE GENERALE ORDINAIRE EXERCICE 2025 - 28/04/2026
Published on 03/26/2026 at 18:17, 18 hours 32 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 18 hours 32 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 18 hours 49 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
